About: XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.64 (-4.58%)
XRTX NASDAQ XORTX Therapeutics Inc
XORTX Therapeutics Inc share price
XRTX price activity
Last Price
$1.640
Change (24hr)
-0.08 USD (-4.58%)
Volume
109.11K
Volume (4w avg)
-
Open
$1.67
Day Range
$1.64 - $1.67
Previous Close
$1.72
Last Trade
13 Oct, 3:49 pm GMT+0
Delayed
13 Oct, 3:49 pm GMT+0
XRTX price performance
Delayed
13 Oct, 3:49 pm GMT+0
XRTX Market Signals